{"organizations": [], "uuid": "0ebc8d653d500c46a5868f37afd6438c68e1cd6f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-european-commission-approves-brist/brief-european-commission-approves-bristol-myers-squibbs-yervoy-idUSFWN1PH0MS", "country": "US", "domain_rank": 408, "title": "BRIEF-European Commission Approves Bristol-Myers Squibb's Yervoy", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-22T14:13:00.000+02:00", "replies_count": 0, "uuid": "0ebc8d653d500c46a5868f37afd6438c68e1cd6f"}, "author": "", "url": "https://www.reuters.com/article/brief-european-commission-approves-brist/brief-european-commission-approves-bristol-myers-squibbs-yervoy-idUSFWN1PH0MS", "ord_in_thread": 0, "title": "BRIEF-European Commission Approves Bristol-Myers Squibb's Yervoy", "locations": [], "entities": {"persons": [{"name": "yervoy reut", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-european commission approves bristol-myers squibb", "sentiment": "negative"}, {"name": "squibb co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "ec", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": " 15 PM / Updated 6 minutes ago BRIEF-European Commission Approves Bristol-Myers Squibb's Yervoy Reuters Staff 1 Min Read \nJan 22 (Reuters) - Bristol-Myers Squibb Co: \n* EUROPEAN COMMISSION APPROVES BRISTOL-MYERS SQUIBBâ€™S YERVOY (IPILIMUMAB) FOR TREATMENT OF PEDIATRIC PATIENTS 12 YEARS AND OLDER WITH UNRESECTABLE OR METASTATIC MELANOMA \n* BRISTOL-MYERS SAYS EC EXPANDED INDICATION OF YERVOY TO INCLUDE TREATMENT OF ADVANCED MELANOMA IN PEDIATRIC PATIENTS 12 YRS OF AGE & OLDER Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-22T14:13:00.000+02:00", "crawled": "2018-01-22T15:01:54.001+02:00", "highlightTitle": ""}